Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 9/20 | 0.56 |
| ▸ | CALCR | P30988 | 3/20 | 0.51 |
| ▸ | CCKBR | P32239 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.49 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31258335 | 0.94 | CXCL8 (0.53) | CXCL8CALCROPRD1NMUR2NMUR1 | |
| SCHEMBL29640709 | 0.92 | NPY2R (0.54) | CXCL8CALCR | |
| SCHEMBL30658198 | 0.85 | CALCR (0.70) | CALCRCCKBROPRM1OPRD1 | |
| SCHEMBL29797079 | 0.84 | OPRD1 (0.53) | CXCL8OPRM1OPRD1 | |
| SCHEMBL30567770 | 0.84 | CALCR (0.60) | CXCL8CALCROPRM1OPRD1 | |
| SCHEMBL30824291 | 0.83 | CALCR (0.57) | CALCR | |
| SCHEMBL29591654 | 0.83 | OPRD1 (0.52) | OPRM1OPRD1NMUR2NMUR1 | |
| SCHEMBL21143353 | 0.83 | OPRM1 (0.56) | OPRM1OPRD1 | |
| SCHEMBL31182806 | 0.82 | CALCR (0.65) | CALCR | |
| SCHEMBL17722479 | 0.81 | CXCL8 (0.62) | CXCL8NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199692-A1 | POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2024-06-20 | — | — | US | disclosed |
| WO-2023204170-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT, FOR LUNG INFLAMMATION AND FIBROSIS, CONTAINING COMPOUND HAVING MMP2 INHIBITORY ACTIVITY AS ACTIVE INGREDIENT | 大正製薬株式会社 | 2023-10-26 | — | — | WO | disclosed |
| EP-4056581-A1 | POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT | Taisho Pharmaceutical Co., Ltd. (JP) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199692-A1 | POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT | MMP2, MMP26, MMP25 | CXCL8 535/4885CALCR 617/4885CCKBR 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.